Galaxy Medicare

Which are the latest news on Galaxy Medicare?

Why is Galaxy Medicare Ltd falling/rising?

As of 05-Sep, Galaxy Medicare Ltd's stock price is stable at 17.85, with a positive trend over the past week and month, outperforming the Sensex. Despite a year-to-date decline of 17.36%, increased investor participation indicates potential for recovery.

As of 05-Sep, Galaxy Medicare Ltd's stock price is currently stable at 17.85, showing no change (0.00%). However, the stock has demonstrated a positive performance trend over the past week and month, with increases of 5.00% and 6.89%, respectively, while the benchmark Sensex has declined by 1.15% and 2.91% during the same periods. This indicates that Galaxy Medicare Ltd is outperforming the market.<BR><BR>Additionally, there has been a notable rise in investor participation, with delivery volume on 02 September increasing by 181.25% compared to the 5-day average. This surge in trading activity suggests growing interest in the stock, which could contribute to its price stability or potential upward movement in the future.<BR><BR>Despite these positive indicators, it is important to note that the stock has a year-to-date decline of 17.36%, which is significantly higher than the Sensex's decline of 8.54%. This longer-term trend may weigh on investor sentiment, but the recent performance and increased trading volume suggest a potential for recovery or stabilization in the near term.

What does Galaxy Medicare do?

Galaxy Medicare Ltd is a micro-cap healthcare services company incorporated in 1992, with a market cap of INR 26 Cr. Key financial metrics include a P/E ratio of 8.00, a dividend yield of 1.76%, and a return on equity of 14.16%.

Overview: <BR>Galaxy Medicare Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History: <BR>Galaxy Medicare Limited was incorporated on July 23, 1992, in the Mancheshwar Industrial area of Bhubaneswar, Orissa. The company commenced its operations in the same year. There is no information available regarding status changes or the latest quarter for which sales and profit are reported.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 26 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 8.00 <BR>Industry P/E: 112 <BR>Dividend Yield: 1.76% <BR>Debt-Equity: 0.17 <BR>Return on Equity: 14.16% <BR>Price-to-Book: 1.07 <BR><BR>Contact Details: <BR>Address: Not available <BR>Phone: Not available <BR>Email: Not available <BR>Website: Not available

Who are the peers of the Galaxy Medicare?

Galaxy Medicare's peers include Sunrest Lifescie, Chennai Meena, Adeshwar Meditex, Tejnaksh Health, and others. Management risk is excellent for Galaxy Medicare and Sunrest Lifescie, while growth is below average for Galaxy Medicare and several peers.

Peers: The peers of Galaxy Medicare are Sunrest Lifescie, Chennai Meena, Adeshwar Meditex, Tejnaksh Health., Samsrita Labs, GKB Ophthalmics, Transgene Biotek, Vanta Bioscience, Deccan Healthcar.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sunrest Lifescie and Galaxy Medicare, while Below Average management risk is found at Adeshwar Meditex, Tejnaksh Health., and GKB Ophthalmics, and the rest. Growth is Excellent at Sunrest Lifescie, Below Average at Galaxy Medicare, Adeshwar Meditex, Tejnaksh Health., Vanta Bioscience, and the rest, while Chennai Meena, Samsrita Labs, and Transgene Biotek do not qualify. Capital Structure is Good at Galaxy Medicare, GKB Ophthalmics, and Deccan Healthcar, Average at Adeshwar Meditex, Below Average at Tejnaksh Health., Vanta Bioscience, and the rest.<BR><BR>Return Snapshot: GKB Ophthalmics has the highest 1-year return at N/A, while Sunrest Lifescie has the lowest at -19.51%, and Galaxy Medicare's 1-year return is also N/A. Additionally, Sunrest Lifescie and Vanta Bioscience have negative six-month returns.

How big is Galaxy Medicare?

Summary could not be generated.

As of 14th August, Galaxy Medicare Ltd has a market capitalization of 30.12 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent quarterly performance data is unavailable, so there are no figures for Net Sales or Net Profit for the latest four quarters.<BR><BR>The reporting period for the balance sheet is March 2025, with Shareholder's Funds amounting to 24.15 Cr and Total Assets valued at 31.49 Cr.